- Email: [email protected]
Subject index to volume 23
850
BIOL PSYCHIATR> 1988;23:850~855
Subject Index to Volume 23
ACTH. See Adrenocorticotrophic hormone (ACTH) Adenylate cyclase antidepressants and, 543 Adrenal function salivary cortisol and, 335 @-adrenergic receptors. 750 quantitative autoradiography of, 750 Adrenocorticotrophic hormone (ACTH) DST and. 531 in elderly, 252 in ethanol-induced euphoria. 14 I Affective disorders. See also .spec$c disorder calcium function in. 367 corticotropin-releasing factor in, 755 melatonin and, 40.5 serotonin effects on H-reflex in. 602 testosterone in. 357 Age evoked potential studies and. 6 I2 Akathisia amitriptyline in. 186 propranolol vs. benztropine in. 21 1-le Alcohol drinking ACTH and, I41 Alcoholism tryptophan conversion and, 89 withdrawal seizures in, 507 Alprazolam adenylate cyclase and. 543 Alzheimer’s disease 4-aminopyridine in, 48S cortisol-naltrexone response in, 726 DST in, 13 physostigmine and P300 in, 321-le Pisa syndrome in, 213-1~ serotonin and, 136 4-aminopyridine in Alzheimer’s disease, 485 Amitriptyline
Ahhrcviurkm ed:
Editorial le. Letter to the Editor
sholinergic supersensitivity and, 2 14-1~ in neuroleptic-induced akathisia. I86 ncuroleptic malignant syndrome and, 321)-ie nicotine supersensitivity and, 320.le Amygdala kindling, 285 Animal models of anxiety, 523, 829 of depression. 7 I I of tongue dyskinesia. IS9 Anorexia nervosa corticotropin-releasmg factor and, S3 CT ?r, 377 serotonin in, 102 \leep in. 99 Antidepressants. See also specific qmrs adenylate cyclasc and, 543 melatonin and. 405 serotonin agonists as. 237 tricyclic with lithium in obsessive-comptli~lve disorder. I KI Anxiety animal model of, S23. 829 DST and, 261, 698 serotonin and. 189 Audiogenic seizures. 734 Auditory evoked potentials P300 and physostigmine in Alzheimer’s disease, 321-k P300 in schizophrenia. 776 .4utism, infantile antibrain antibodies in. 644 Autoradiography of P-adrenergic receptors. 750 Benzodiazepines serotonin and, I89 Benztropine propranolol vs. in akathisia, 21 I-lc Beta-casein in postpartum psychosis, I IS Biological Psyhiatry editorial policy, 7Wed Bipolar disorder primitive reflexes in, 791 Brain mapping, 63X
Subject Index to Volume 23
Brain tumor ECT with, 176 Bulimia neuropeptide Y in, 53 sleep in, 99 TRH response in, 476 Buspirone in learned helplessness,
237
Caffeine dopamine and, 761 Calcium in affective disorders, 367 psychiatric symptoms and. 149 Captopril in depression, 637 Carbamazepine in posttraumatic stress disorder. 642 Catecholamincs antidepressant response and, 543 methylphenjdate effects on. 350 Cerebrospinal fluid (CSF) creatinine in. 586 glut~matc-~l~)noamine relationships in, 689 research with. 3 17-le Cholecystokinin eating disorders and, 53 Chronic pain syndrome depression and, 86 Clonidine and DST in Alzheimer’s disease. 13 Clozapine dopamine transmission and. 497 Cocaine abuse status epilepticus in, 515 Computed tomography (CT) in anorexia nervosa, 377 Conflicts of interest. 215ed Cornell Scale for Depression in Dementia, 271 CORRESPONDENCE
Amitriptyline and cholincrgic supersensitivity, 214 Creation, evolution, and biological psychiatry, 209 Different patterns of local brain energy metabolism. 214 Glycinc therapy of schizophrenia, 210 Increased CSF amino acids and ventricular eniargement. 3 17 Neuroleptic-induced akathisia: Propranolol versus benztropine, 2 I 1
BIOL PSYCHlATRY 1988:23:850-855
851
Neuroleptjc malignant syndrome. amitriptyiine. and thioridazine, 320 Occipital slow EEG rhythms (3-6 Hz activity), an unreliable marker, 3 18 Physostigmine, auditory P300, and Alzheimer’s disease (with response), 321 Pisa syndrome in Alzheimer’s disease, 2 I3 Tardive dysmentia in Hungary, 429 Thyroid hormones during sleep deprivation. 537 Corticotropin-releasing factor in affective disorders, 755 in anorexia nervosa, 53 in chronic pain and/or depression, 86 Cortisol in elderfy. 252 MK-212 and. 818 naftrexone response in Alzhcimer’s disease. 726 in panic disorder. 575 salivary, 335 sexual dysfunction and, 527 Creatinine in schizophrenia, 586 CSF. See Cerebrospinal fluid (CSF) CT. See Computed tomography (CT) CycloFOXY in PET. 435 Dementia Cornell scale for depression in, 271 Depression alprazolam response in, 543 animal model of, 71 I calcium function in, 367 captopril in. 637 chronic pain and. 86 -dementia scale. 27 1 desipramine imipramine-binding effects in. 397 ECT effect on endo~hins in, 459 leuk[~encepha~opathy in, 5 19 .MAO-serotonin activity in, 44 MHPG and imipramine binding in, 560 mononuclear leukocyte TSH production in. 797 platelet serotonin uptake in, 833 prostaglandins in, 326 seasonal variation of imipramine binding in. 217 starvation and, 7 I9 treatment and DST response in. 705 Desipramine imipramine binding effects of, 397 Dexamethasone Suppression Test (DST) ACTH and. 531
852
BIOL PSYCHIATRY 1988:23:850-855
Subject Index to Volume 23
in Alzheimer’s disease, 13 anxiety and, 698 in anxiety disorder, 261 in elderly, 252 endorphins and, 53 1 learned helplessness model and, 388 in sexual dysfunction, 527 tobacco withdrawal and, 96 treatment of depression and, 705 Dogs genetically nervous, 523, 829 Dopamine caffeine effects on, 761 eating disorders and, 53 kindled seizures and. 285 neuroleptic effects on. 497 Down’s syndrome olfaction in. 837 DST. See Dexamethasone Suppression Test (DST) Eating disorders neurobiology of, 53 sleep in, 99 starvation and depression TRH response in. 476 ECT. See Electroconvulsive
in. 719 therapy (ECT)
EDITORlA1.S
Are statistics necessary’! 1 Conflicts of interest, 2 I5 The history of psychiatry, 107 A message from the president of the Society for Biological Psychiatry. 325 Privitization, 433 Quality of life, 541 Report from the editorial office, 759 The whereabouts of the why, 651 EEG See Electroencephalography (EEG) Elderly Cornell scale for. 271 DST in, 2.52 Electroconvulsive therapy ( ECTl endorphins and, 459 lithium with, 595 in patient with brain tumor, 176 serotonergic receptors in, 807 Electroencephalography (EEG) of brain dysfunction in schizophrenia, 295 brain mapping by, 628 of posttraumatic stress disorder, 642 rhythmic midtemporal discharges in, 741 slow occipital rhythms in, 3 18-1~ Endorphins
DST and, 531 ECT effect on, 450 Euphoria ethanol-induced, 141 Evoked potentials a&e and gender effects on. 6 I2 auditory in Alzheimer’s disease, 321.le auditory in schizophrenia, 776 Experimentation conflicts of interest in, 215-ed corporate support ot. 433-ed with CSF. 3 17-1~ statistics in, I-ed. 79 Extroversion-introversion theta rhythm and MAO in, 3 I Fear motor activity and. 523 opioids and, 426 Frontal midline theta activity MA0 and, 3 I GABA anxiety and. t8Y suicide and, I09 Gender evoked potential studies and, 612 Glutamate-monoamine relationships, 689 Glycine in schizophrenia. 2iO-ie Graves’ disease propranolol in. h7X Haloperidol dopamine transmission and, 497 latent inhibition and, 746 Heart rate in genetically nervous dogs, 829 Helplessness, learned as DST model, 388 serotonin and. 237 Hoffman reflex serotonin and. 602 5-hydroxyindolacetic acid (5-HIAA) in anorexia nervosa, 102 5-hydroxytryptophan hypothalamic injection of, 7 I I Hyperactivity imipramine binding in, 491 methylphenidate effect on catecholamincs 350 Hyperparathyroidism
in.
BIOL PSYCHIATRY 1988;23:8.5~855
Subject Index to Volume 23
psychiatric symptoms in, 149 Hyponatremia, psychosis, and polydipsia. syndrome
See PIP
Imipramine MAO-serotonin activity and, 44 lmipramine binding depressive symptomatology and. 560 desipramine and, 397 in hyperactivity, 491 seasonal variation in, 217 Immune response in infantile autism, 644 stress and. 209.le Impotence DST in. 527 Infantile autism antibrain antibodies in, 644 Information processing visual in schizophrenia, 3, 664 Ketamine in tongue dyskinesia
model,
159
Latent inhibition haloperidol and. 746 Leukoencephalopathy in depression. 5 I9 Ligand binding. 435 Lithium ECT with, 595 NMR measurement of, 465 in PIP syndrome. 25 with tricyclics in obsessive-compulsive I81
disorder,
Mania opioids and, 426 tardive dystonia with, 3 I2 MAO. See Monoamine oxidase Melatonin, 405 Memory in schizophrenia with tardive dyskinesia, 129 Methylphenidatc catecholamine effects in hyperactivity. 350 MHPG depressive symptomatology and, 560 in panic disorder, 575 MK-212. 818 Monoamine metabolites -glutamate relationships, 689 in hyperparathyroidism, 149
853
Monoamine oxidase (MAO) in schizophrenia, 93 serotonin activity in depression, 44 short- and long-term inhibition of, 227 theta rhythm and, 31 Mononuclear leukocyte -TSH responsiveness in depression, 797 Motor activity in genetically nervous dogs, 523 Naltrexone cortisol response in Alzheimer’s disease. 726 National Institutes of Health, 433-ed N-CAM. See Neural cell adhesion molecule (NCAM) Neural cell adhesion molecule (N-CAM) in schizophrenia, 769 Neuroleptic(s) amitriptyline in akathisia induced by. 186 benztropine vs. propranolol in akathisia induced by, 21 I-le dopamine transmission and, 497 MAO and. 93 olfaction and, 123 PET studies of, 653 Pisa syndrome and, 213.le Neuroleptic malignant syndrome amitriptyline and thioridazine withdrawal and, 320~le Neuropeptide Y in bulimia, 53 Neurotransmitters eating disorders and, 53 suicide and, 109 Nicotine amitriptyline and, 169 NMR. See Nuclear magnetic resonance (NMR) Norepinephrine eating disorders and, 53 Nuclear magnetic resonance (NMR) lithium measurement by, 465 Obsessive-compulsive disorder lithium-tricyclic treatment of. I8 I serotonin and, I89 Occipital slow EEG rhythms. 318-le Olfaction in Down’s syndrome. 837 in schizophrenia. 123 Opioids eating disorders and, 53 ECT effect on. 459
854
BIOL PSYC’HIATR\ 198X.‘3:85@ 8x5
in fear and mama, 426 in postpartum psychosis, receptor subtypes. 435
1IS
Pain depression and, 86 Panic disorder cortisol and MHPG in, 575 serotonin and. 189 Paranoid schizophr~n~~~ visible persistencein. .? PET. See Positron emission tomography !PET) Phenytoin in PIP syndrome. 25 Physostigmine auditory P300 and, 32 1-le DST and, 13 Pineal gland audiogenic seizures and, 734 PIP syndrome lithium and phenytoin in, 25 Pisa syndrome, 2 13le Poiydips~a. psychosis. and hy~natrem~a. See PIP syndrome Positron emission tomography (PET) cycIoFOXY in. 435 drug receptor occupancy studies by. 653 Postpartum psychosis beta-casein levels in. I IS Posttraumatic stress disorder, 642 Preattentive processing in schizophrenia. 664 Prolactin MK-212 and. 818 Propranolo~ ~nz~rop~ne vs. in akathisia. 211 -le in Graves’ disease. 678 Prostaglandins in depression. 326 Psychiatry history of, 107~ed melatonin in. 405 Psychosis in hyperparathyroidism , I49 hyponatremia and polydipsia with. See PIP syndrome ~stpa~m, I IS Publication. 759-ed Quality of life, 541~cd Quantitative autoradiography of P-adrenergic receptors.
750
Kat s-hydroxytryptophan injection in. 7I X learned helplessness in. 388 kindled seizures in. 285 scrotonin and helplessness behavmr in, 2.;; short- and long-term MAO inhibition in, 11’7 tongue dyskinesia m, 159
Keflcxs primitive in tardive dyskincsia, 7Yt serotonin effects on. 602 Research conflicts of interest in, 215ed with CSF, 317-1~ privitization of. 43%ed publication of. 75%ed statistics in, Led. 79 Rhythmic midtemporal discharges. 74’1 Saccadic eye movements in schizophrenia. 670 Sahvary measuremcnls of anxiety with DST. 698 cortisol, 335 pros~glandin, 3% Schizophrenia bilateral brain dysfunction in, 295 CSF creatininc ni. 586 glycinc in, 210-1~ kindled seizures and. 285 MAO in. 93 melatonin in, 405 memory and tardivc dyskinesia in. I29 N-CAM serum fragment in. 769 olfactory deficits in. 123 P300 in. 776 PET drug receptor studies jn, 653 preattentive processmg deficit in, 664 primitive reflexes in. 791 saccadic eye movement control in. 670 serotonin in. 243 testosterone in . 3-Yt visible persistence in, 3 Seasonal variation in imipramine binding. 2 I7 Seizures afcohoi withdrawal, 507 ~~~ygdaIa-kindle, 285 cocaine abuse and. 5 IS pincal gland and. 734 Scrotonin alcoholism and. 89 Alzheimer‘s disease and. 136
Sub,ject Index to Volume 23
BIOLPSYCHIATRY 1988:23:850-x55
overuse of, I-ed. 79 Status epilepticus in cocaine abuse, 515 Stress immune response and, 209~le Suicide GABA and. 109
primitive reflexes in. 791 Tardive dysmentia, 429-le Tardive dystonia. See Tardive dyskinesia Testosterone in affective disorders vs. schizophrenia. 357 Theta rhythm platelet MAO and, 31 Thioridazine neuroleptic malignant syndrome and, 320 Thyroid hormones during sleep deprivation. 537-1~ Thyrotropin (TSH) mononucle~ leukocyte production of in depression. 797 Thyrotropin-releasing hormone (TRHI response to in bulimia, 476 Tongue dyskinesia animal model of, 159 Topographic brain maps, 628 Tranylcypromine short- and long-term effects of, 227 TRH. SW Thyrotropin-releasing hormone Tryptophan -kynurenine conversion in newly abstinent alcoholics. 89 TSH. See Thyrotropin (TSH)
Tardive dyskinesia amitriptyiinc vs. akathisia in, 186 animal model of, 159 mania with, 312 memory and. 129
Ventricular enlargement in anorexia nervosa, 377 CSF studies and. 317-Ie Visible persistence in paranoid schizophrenia,
anxiety and, 189 eating disorders and, 53, 102 -H-reflex effects, 602 learned helplessness and, 237 -MAO activity in depression, 44 MK-212 agonist to, 818 platelet uptake of in depression, 833 receptors for in ECT, 807 schizophrenia and, 243 Sexual dysfunction DST in. 527 Sleep in eating disorders, 99 Sleep d~privatiol~ thyroid hormones during, 537-le Smoking DST and withdrawal from, 96 Starvation, 7 19
Statistics
3
855
BIOL PSYCHIATR> 1988;23:850~855
Subject Index to Volume 23
ACTH. See Adrenocorticotrophic hormone (ACTH) Adenylate cyclase antidepressants and, 543 Adrenal function salivary cortisol and, 335 @-adrenergic receptors. 750 quantitative autoradiography of, 750 Adrenocorticotrophic hormone (ACTH) DST and. 531 in elderly, 252 in ethanol-induced euphoria. 14 I Affective disorders. See also .spec$c disorder calcium function in. 367 corticotropin-releasing factor in, 755 melatonin and, 40.5 serotonin effects on H-reflex in. 602 testosterone in. 357 Age evoked potential studies and. 6 I2 Akathisia amitriptyline in. 186 propranolol vs. benztropine in. 21 1-le Alcohol drinking ACTH and, I41 Alcoholism tryptophan conversion and, 89 withdrawal seizures in, 507 Alprazolam adenylate cyclase and. 543 Alzheimer’s disease 4-aminopyridine in, 48S cortisol-naltrexone response in, 726 DST in, 13 physostigmine and P300 in, 321-le Pisa syndrome in, 213-1~ serotonin and, 136 4-aminopyridine in Alzheimer’s disease, 485 Amitriptyline
Ahhrcviurkm ed:
Editorial le. Letter to the Editor
sholinergic supersensitivity and, 2 14-1~ in neuroleptic-induced akathisia. I86 ncuroleptic malignant syndrome and, 321)-ie nicotine supersensitivity and, 320.le Amygdala kindling, 285 Animal models of anxiety, 523, 829 of depression. 7 I I of tongue dyskinesia. IS9 Anorexia nervosa corticotropin-releasmg factor and, S3 CT ?r, 377 serotonin in, 102 \leep in. 99 Antidepressants. See also specific qmrs adenylate cyclasc and, 543 melatonin and. 405 serotonin agonists as. 237 tricyclic with lithium in obsessive-comptli~lve disorder. I KI Anxiety animal model of, S23. 829 DST and, 261, 698 serotonin and. 189 Audiogenic seizures. 734 Auditory evoked potentials P300 and physostigmine in Alzheimer’s disease, 321-k P300 in schizophrenia. 776 .4utism, infantile antibrain antibodies in. 644 Autoradiography of P-adrenergic receptors. 750 Benzodiazepines serotonin and, I89 Benztropine propranolol vs. in akathisia, 21 I-lc Beta-casein in postpartum psychosis, I IS Biological Psyhiatry editorial policy, 7Wed Bipolar disorder primitive reflexes in, 791 Brain mapping, 63X
Subject Index to Volume 23
Brain tumor ECT with, 176 Bulimia neuropeptide Y in, 53 sleep in, 99 TRH response in, 476 Buspirone in learned helplessness,
237
Caffeine dopamine and, 761 Calcium in affective disorders, 367 psychiatric symptoms and. 149 Captopril in depression, 637 Carbamazepine in posttraumatic stress disorder. 642 Catecholamincs antidepressant response and, 543 methylphenjdate effects on. 350 Cerebrospinal fluid (CSF) creatinine in. 586 glut~matc-~l~)noamine relationships in, 689 research with. 3 17-le Cholecystokinin eating disorders and, 53 Chronic pain syndrome depression and, 86 Clonidine and DST in Alzheimer’s disease. 13 Clozapine dopamine transmission and. 497 Cocaine abuse status epilepticus in, 515 Computed tomography (CT) in anorexia nervosa, 377 Conflicts of interest. 215ed Cornell Scale for Depression in Dementia, 271 CORRESPONDENCE
Amitriptyline and cholincrgic supersensitivity, 214 Creation, evolution, and biological psychiatry, 209 Different patterns of local brain energy metabolism. 214 Glycinc therapy of schizophrenia, 210 Increased CSF amino acids and ventricular eniargement. 3 17 Neuroleptic-induced akathisia: Propranolol versus benztropine, 2 I 1
BIOL PSYCHlATRY 1988:23:850-855
851
Neuroleptjc malignant syndrome. amitriptyiine. and thioridazine, 320 Occipital slow EEG rhythms (3-6 Hz activity), an unreliable marker, 3 18 Physostigmine, auditory P300, and Alzheimer’s disease (with response), 321 Pisa syndrome in Alzheimer’s disease, 2 I3 Tardive dysmentia in Hungary, 429 Thyroid hormones during sleep deprivation. 537 Corticotropin-releasing factor in affective disorders, 755 in anorexia nervosa, 53 in chronic pain and/or depression, 86 Cortisol in elderfy. 252 MK-212 and. 818 naftrexone response in Alzhcimer’s disease. 726 in panic disorder. 575 salivary, 335 sexual dysfunction and, 527 Creatinine in schizophrenia, 586 CSF. See Cerebrospinal fluid (CSF) CT. See Computed tomography (CT) CycloFOXY in PET. 435 Dementia Cornell scale for depression in, 271 Depression alprazolam response in, 543 animal model of, 71 I calcium function in, 367 captopril in. 637 chronic pain and. 86 -dementia scale. 27 1 desipramine imipramine-binding effects in. 397 ECT effect on endo~hins in, 459 leuk[~encepha~opathy in, 5 19 .MAO-serotonin activity in, 44 MHPG and imipramine binding in, 560 mononuclear leukocyte TSH production in. 797 platelet serotonin uptake in, 833 prostaglandins in, 326 seasonal variation of imipramine binding in. 217 starvation and, 7 I9 treatment and DST response in. 705 Desipramine imipramine binding effects of, 397 Dexamethasone Suppression Test (DST) ACTH and. 531
852
BIOL PSYCHIATRY 1988:23:850-855
Subject Index to Volume 23
in Alzheimer’s disease, 13 anxiety and, 698 in anxiety disorder, 261 in elderly, 252 endorphins and, 53 1 learned helplessness model and, 388 in sexual dysfunction, 527 tobacco withdrawal and, 96 treatment of depression and, 705 Dogs genetically nervous, 523, 829 Dopamine caffeine effects on, 761 eating disorders and, 53 kindled seizures and. 285 neuroleptic effects on. 497 Down’s syndrome olfaction in. 837 DST. See Dexamethasone Suppression Test (DST) Eating disorders neurobiology of, 53 sleep in, 99 starvation and depression TRH response in. 476 ECT. See Electroconvulsive
in. 719 therapy (ECT)
EDITORlA1.S
Are statistics necessary’! 1 Conflicts of interest, 2 I5 The history of psychiatry, 107 A message from the president of the Society for Biological Psychiatry. 325 Privitization, 433 Quality of life, 541 Report from the editorial office, 759 The whereabouts of the why, 651 EEG See Electroencephalography (EEG) Elderly Cornell scale for. 271 DST in, 2.52 Electroconvulsive therapy ( ECTl endorphins and, 459 lithium with, 595 in patient with brain tumor, 176 serotonergic receptors in, 807 Electroencephalography (EEG) of brain dysfunction in schizophrenia, 295 brain mapping by, 628 of posttraumatic stress disorder, 642 rhythmic midtemporal discharges in, 741 slow occipital rhythms in, 3 18-1~ Endorphins
DST and, 531 ECT effect on, 450 Euphoria ethanol-induced, 141 Evoked potentials a&e and gender effects on. 6 I2 auditory in Alzheimer’s disease, 321.le auditory in schizophrenia, 776 Experimentation conflicts of interest in, 215-ed corporate support ot. 433-ed with CSF. 3 17-1~ statistics in, I-ed. 79 Extroversion-introversion theta rhythm and MAO in, 3 I Fear motor activity and. 523 opioids and, 426 Frontal midline theta activity MA0 and, 3 I GABA anxiety and. t8Y suicide and, I09 Gender evoked potential studies and, 612 Glutamate-monoamine relationships, 689 Glycine in schizophrenia. 2iO-ie Graves’ disease propranolol in. h7X Haloperidol dopamine transmission and, 497 latent inhibition and, 746 Heart rate in genetically nervous dogs, 829 Helplessness, learned as DST model, 388 serotonin and. 237 Hoffman reflex serotonin and. 602 5-hydroxyindolacetic acid (5-HIAA) in anorexia nervosa, 102 5-hydroxytryptophan hypothalamic injection of, 7 I I Hyperactivity imipramine binding in, 491 methylphenidate effect on catecholamincs 350 Hyperparathyroidism
in.
BIOL PSYCHIATRY 1988;23:8.5~855
Subject Index to Volume 23
psychiatric symptoms in, 149 Hyponatremia, psychosis, and polydipsia. syndrome
See PIP
Imipramine MAO-serotonin activity and, 44 lmipramine binding depressive symptomatology and. 560 desipramine and, 397 in hyperactivity, 491 seasonal variation in, 217 Immune response in infantile autism, 644 stress and. 209.le Impotence DST in. 527 Infantile autism antibrain antibodies in, 644 Information processing visual in schizophrenia, 3, 664 Ketamine in tongue dyskinesia
model,
159
Latent inhibition haloperidol and. 746 Leukoencephalopathy in depression. 5 I9 Ligand binding. 435 Lithium ECT with, 595 NMR measurement of, 465 in PIP syndrome. 25 with tricyclics in obsessive-compulsive I81
disorder,
Mania opioids and, 426 tardive dystonia with, 3 I2 MAO. See Monoamine oxidase Melatonin, 405 Memory in schizophrenia with tardive dyskinesia, 129 Methylphenidatc catecholamine effects in hyperactivity. 350 MHPG depressive symptomatology and, 560 in panic disorder, 575 MK-212. 818 Monoamine metabolites -glutamate relationships, 689 in hyperparathyroidism, 149
853
Monoamine oxidase (MAO) in schizophrenia, 93 serotonin activity in depression, 44 short- and long-term inhibition of, 227 theta rhythm and, 31 Mononuclear leukocyte -TSH responsiveness in depression, 797 Motor activity in genetically nervous dogs, 523 Naltrexone cortisol response in Alzheimer’s disease. 726 National Institutes of Health, 433-ed N-CAM. See Neural cell adhesion molecule (NCAM) Neural cell adhesion molecule (N-CAM) in schizophrenia, 769 Neuroleptic(s) amitriptyline in akathisia induced by. 186 benztropine vs. propranolol in akathisia induced by, 21 I-le dopamine transmission and, 497 MAO and. 93 olfaction and, 123 PET studies of, 653 Pisa syndrome and, 213.le Neuroleptic malignant syndrome amitriptyline and thioridazine withdrawal and, 320~le Neuropeptide Y in bulimia, 53 Neurotransmitters eating disorders and, 53 suicide and, 109 Nicotine amitriptyline and, 169 NMR. See Nuclear magnetic resonance (NMR) Norepinephrine eating disorders and, 53 Nuclear magnetic resonance (NMR) lithium measurement by, 465 Obsessive-compulsive disorder lithium-tricyclic treatment of. I8 I serotonin and, I89 Occipital slow EEG rhythms. 318-le Olfaction in Down’s syndrome. 837 in schizophrenia. 123 Opioids eating disorders and, 53 ECT effect on. 459
854
BIOL PSYC’HIATR\ 198X.‘3:85@ 8x5
in fear and mama, 426 in postpartum psychosis, receptor subtypes. 435
1IS
Pain depression and, 86 Panic disorder cortisol and MHPG in, 575 serotonin and. 189 Paranoid schizophr~n~~~ visible persistencein. .? PET. See Positron emission tomography !PET) Phenytoin in PIP syndrome. 25 Physostigmine auditory P300 and, 32 1-le DST and, 13 Pineal gland audiogenic seizures and, 734 PIP syndrome lithium and phenytoin in, 25 Pisa syndrome, 2 13le Poiydips~a. psychosis. and hy~natrem~a. See PIP syndrome Positron emission tomography (PET) cycIoFOXY in. 435 drug receptor occupancy studies by. 653 Postpartum psychosis beta-casein levels in. I IS Posttraumatic stress disorder, 642 Preattentive processing in schizophrenia. 664 Prolactin MK-212 and. 818 Propranolo~ ~nz~rop~ne vs. in akathisia. 211 -le in Graves’ disease. 678 Prostaglandins in depression. 326 Psychiatry history of, 107~ed melatonin in. 405 Psychosis in hyperparathyroidism , I49 hyponatremia and polydipsia with. See PIP syndrome ~stpa~m, I IS Publication. 759-ed Quality of life, 541~cd Quantitative autoradiography of P-adrenergic receptors.
750
Kat s-hydroxytryptophan injection in. 7I X learned helplessness in. 388 kindled seizures in. 285 scrotonin and helplessness behavmr in, 2.;; short- and long-term MAO inhibition in, 11’7 tongue dyskinesia m, 159
Keflcxs primitive in tardive dyskincsia, 7Yt serotonin effects on. 602 Research conflicts of interest in, 215ed with CSF, 317-1~ privitization of. 43%ed publication of. 75%ed statistics in, Led. 79 Rhythmic midtemporal discharges. 74’1 Saccadic eye movements in schizophrenia. 670 Sahvary measuremcnls of anxiety with DST. 698 cortisol, 335 pros~glandin, 3% Schizophrenia bilateral brain dysfunction in, 295 CSF creatininc ni. 586 glycinc in, 210-1~ kindled seizures and. 285 MAO in. 93 melatonin in, 405 memory and tardivc dyskinesia in. I29 N-CAM serum fragment in. 769 olfactory deficits in. 123 P300 in. 776 PET drug receptor studies jn, 653 preattentive processmg deficit in, 664 primitive reflexes in. 791 saccadic eye movement control in. 670 serotonin in. 243 testosterone in . 3-Yt visible persistence in, 3 Seasonal variation in imipramine binding. 2 I7 Seizures afcohoi withdrawal, 507 ~~~ygdaIa-kindle, 285 cocaine abuse and. 5 IS pincal gland and. 734 Scrotonin alcoholism and. 89 Alzheimer‘s disease and. 136
Sub,ject Index to Volume 23
BIOLPSYCHIATRY 1988:23:850-x55
overuse of, I-ed. 79 Status epilepticus in cocaine abuse, 515 Stress immune response and, 209~le Suicide GABA and. 109
primitive reflexes in. 791 Tardive dysmentia, 429-le Tardive dystonia. See Tardive dyskinesia Testosterone in affective disorders vs. schizophrenia. 357 Theta rhythm platelet MAO and, 31 Thioridazine neuroleptic malignant syndrome and, 320 Thyroid hormones during sleep deprivation. 537-1~ Thyrotropin (TSH) mononucle~ leukocyte production of in depression. 797 Thyrotropin-releasing hormone (TRHI response to in bulimia, 476 Tongue dyskinesia animal model of, 159 Topographic brain maps, 628 Tranylcypromine short- and long-term effects of, 227 TRH. SW Thyrotropin-releasing hormone Tryptophan -kynurenine conversion in newly abstinent alcoholics. 89 TSH. See Thyrotropin (TSH)
Tardive dyskinesia amitriptyiinc vs. akathisia in, 186 animal model of, 159 mania with, 312 memory and. 129
Ventricular enlargement in anorexia nervosa, 377 CSF studies and. 317-Ie Visible persistence in paranoid schizophrenia,
anxiety and, 189 eating disorders and, 53, 102 -H-reflex effects, 602 learned helplessness and, 237 -MAO activity in depression, 44 MK-212 agonist to, 818 platelet uptake of in depression, 833 receptors for in ECT, 807 schizophrenia and, 243 Sexual dysfunction DST in. 527 Sleep in eating disorders, 99 Sleep d~privatiol~ thyroid hormones during, 537-le Smoking DST and withdrawal from, 96 Starvation, 7 19
Statistics
3
855